An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06589596

Public ClinicalTrials.gov record NCT06589596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors

Study identification

NCT ID: NCT06589596
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: BeOne Medicines; Industry
Enrollment: 525 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

BG-89894 Drug
BGB-58067 Drug
Standard of Care Therapy Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 9, 2025
Primary completion: Sep 29, 2027
Completion: Sep 29, 2027
Last update posted: May 11, 2026

2025 – 2027

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 9

Facility	City	State	ZIP	Site status
Usc Norris Comprehensive Cancer Center (Nccc)	Los Angeles	California	90089-1019	Recruiting
Adventhealth	Celebration	Florida	34747-4606	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215-5418	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110-1010	Recruiting
Nyu Langone Health	New York	New York	10016-2708	Recruiting
Columbia University Medical Center	New York	New York	10032	Recruiting
Sidney Kimmel Cancer Center	Philadelphia	Pennsylvania	19107-4307	Recruiting
The University of Texas Md Anderson Cancer Center	Houston	Texas	77030-4009	Recruiting
Next Dallas	Irving	Texas	75039-2743	Recruiting
Next Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06589596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 11, 2026 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06589596 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →